Fiche centre
Research Site
Gdansk — Poland
Essais liés2clinical trials
VilleGdansklocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06909253
Essais cliniques associés
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Trastuzumab deruxtecan | Parkinson | Phase 3 | NCT06989112 | DE-01 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | RECRUITING |
| Ravulizumab | Myasthénie | À vérifier | NCT06909253 | MG-ARCADIA — Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis | RECRUITING |